J Pediatr Genet 2021; 10(04): 323-325
DOI: 10.1055/s-0040-1714361
Case Report

Novel UGT1A1 Gene Mutations in a Boy with Crigler–Najjar Syndrome Type II

Authors

  • David Pérez-Solís

    1   Department of Pediatrics, San Agustín University Hospital, Avilés, Spain
  • Bárbara Montes-Zapico

    1   Department of Pediatrics, San Agustín University Hospital, Avilés, Spain
  • Ana-Cristina Rodríguez-Dehli

    1   Department of Pediatrics, San Agustín University Hospital, Avilés, Spain
  • María García-Hoyos

    2   Department of Medical Genetics, The National Institute of Genomic Medicine, S.L. Paterna, Spain
  • Mireia Arroyo-Hernández

    1   Department of Pediatrics, San Agustín University Hospital, Avilés, Spain

Funding None.

Abstract

In this article, we reported a patient with Crigler–Najjar syndrome type II with high-unconjugated bilirubin levels that decreased after phenobarbital treatment. The patient had two novel missense mutations in the UGT1A1 gene and a promoter variant in one allele. One mutation was c.1001T > C, that predicted leucine to proline substitution at position 334 (p.Leu334Pro). The other, c.1139A > G, predicted glutamic acid to glycine replacement at position 380 (p.Glu380Gly). In silico analysis indicated that both mutations are likely pathogenic.

Note

Written informed parental consent was obtained for both print and online publication of this case.




Publication History

Received: 09 May 2020

Accepted: 07 June 2020

Article published online:
29 July 2020

© 2020. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany